Enargan, Leizel B.
HRN: 27-25-14 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/04/2025
CEFTRIAXONE 1G (VIAL)
06/04/2025
06/11/2025
IV
2g
OD
CAP MR
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes